Clinical Trial

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study is being conducted to investigate the PK, safety, and tolerability of opemalirsen in participants with renal impairment, compared to participants with normal renal function.
Protocol Amendment History 3 changes
critical Trial completed 2026-06-27
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-23
notable Enrollment reduced: 50 -> 34 participants 2026-05-23
Trial Details
NCT Number NCT07154901
Lead Sponsor AstraZeneca
Conditions Renal Impairment
Enrollment 35 participants
Start Date 2025-08-18
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-26